Imaging in multiple myeloma

Recent Results in Cancer Research

Volumn 183, Issue , 2011, Pages 133-147

  Delorme, Stefan ^a   Baur Melnyk, Andrea ^b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18;

ARTICLE; BONE DESTRUCTION; BONE RADIOGRAPHY; BONE SCINTISCANNING; CANCELLOUS BONE; CANCER CHEMOTHERAPY; CANCER INFILTRATION; CANCER STAGING; CANCER SURVIVAL; CONTRAST ENHANCEMENT; CORRELATION ANALYSIS; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DIFFUSION WEIGHTED IMAGING; DRUG TUMOR LEVEL; FUNCTIONAL MORPHOLOGY; HUMAN; IMAGE PROCESSING; METASTASIS; MULTIPLE MYELOMA; PATHOLOGICAL ANATOMY; PATIENT MONITORING; PLASMA CELL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; SENSITIVITY AND SPECIFICITY; SOLID TUMOR; TREATMENT RESPONSE; WHOLE BODY CT;

BONE MARROW; FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE MYELOMA; NEOPLASM STAGING; PLASMACYTOMA; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79955628581     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-540-85772-3_7     Document Type: Article

References (32)

1. Baur A, Stäbler A, Bartl R, Lamerz R, Reiser M (1996) Infiltrationsmuster des Plasmozytoms in der Magnetresonanztomographie. Fortschr Röntgenstr 164:457-463
2. Baur A, Stäbler A, Steinborn M, Schnarkowski P, Pistitsch C, Lamerz R, Bartl R, Reiser M (1998) Magnetresonanztomographie beim Plasmozytom: Wertigkeit verschiedener Sequenzen bei diffuser und fokaler Infiltrationsform. Fortschr Röntgenstr 168:323-329 (Pubitemid 28202257)
3. Baur A, Stäbler A, Nagel D, Lamerz R, Bartl R, Hiller E, Wendtner C, Bachner F, Reiser M (2002) Magnetic resonance imaging as a supplement for the clinical staging system of Durie and Salmon? Cancer 95:1334-1345
4. Baur A, Bartl R, Pellengahr C, Baltin V, Reiser M (2004) Neovascularization of bone marrow in patients with diffuse multiple myeloma: a correlative study of magnetic resonance imaging and histopathologic findings. Cancer 101:2599-2604 (Pubitemid 39532290)
5. Baur-Melnyk A, Buhmann S, Durr HR, Reiser M (2005) Role of MRI for the diagnosis and prognosis of multiple myeloma. Eur J Radiol 55:56-63 (Pubitemid 40798488)
6. Baur-Melnyk A, Buhmann S, Becker C, Schoenberg SO, Lang N, Bartl R, Reiser MF (2008) Whole-body MRI versus whole-body MDCT for staging of multiple myeloma. Am J Roentgenol 190:1097-1104 (Pubitemid 351571514)
7. Bredella MA, Caputo GR, Steinbach LS (2002) Value of FDG positron emission tomography in conjunction with MR imaging for evaluating therapy response in patients with musculoskeletal sarcomas. Am J Roentgenol 179:1145-1150 (Pubitemid 35204364)
8. Bredella MA, Steinbach L, Caputo G, Segall G, Hawkins R (2005) Value of FDG PET in the assessment of patients with multiple myeloma. Am J Roentgenol 184:1199-1204 (Pubitemid 43821897)
9. Cuenod CA, Laredo JD, Chevret S, Hamze B, Naouri JF, Chapaux X, Bondeville JM, Tubiana JM (1996) Acute vertebral collapse due to osteoporosis or malignancy: appearance on unenhanced and gadolinium-enhanced MR images. Radiology 199:541-549 (Pubitemid 26122009)
10. Dispenzieri A, Rajkumar SV, Gertz MA, Fonseca R, Lacy MQ, Bergsagel PL, Kyle RA, Greipp PR, Witzig TE, Reeder CB, Lust JA, Russell SJ, Hayman SR, Roy V, Kumar S, Zeldenrust SR, Dalton RJ, Stewart AK (2007) Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc 82:323-341 (Pubitemid 46348934)
11. Durie BG (2006) The role of anatomic and functional staging in myeloma: description of Durie/Salmon plus staging system. Eur J Cancer 42:1539-1543
12. Durie BG, Salmon SE (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36(3):842-854
13. Durie BG, Waxman AD, D'Agnolo A, Williams CM (2002) Whole-body (18)F-FDG PET identifies high-risk myeloma. J Nucl Med 43:1457-1463 (Pubitemid 35285870)
14. Fonti R, Salvatore B, Quarantelli M, Sirignano C, Segreto S, Petruzziello F, Catalano L, Liuzzi R, Rotoli B, Del Vecchio S, Pace L, Salvatore M (2008) 18 F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma. J Nucl Med 49:195-200 (Pubitemid 351225656)
15. Hillengass J, Wasser K, Delorme S, Kiessling F, Zechmann C, Benner A, Kauczor HU, Ho AD, Goldschmidt H, Moehler T (2007) Lumbar bone marrow microcirculation measurements from dynamic contrast-enhanced MRI is a predictor of event-free survival in progressive multiple myeloma. Clin Cancer Res 13:475-481 (Pubitemid 46225352)
16. Horger M, Kanz L, Denecke B, Vonthein R, Pereira P, Claussen CD, Driessen C (2007) The benefit of using whole-body, low-dose, nonenhanced, multidetector computed tomography for follow-up and therapy response monitoring in patients with multiple myeloma. Cancer 109:1617-1626 (Pubitemid 46595698)
17. Hur J, Yoon CS, Ryu YH, Yun MJ, Suh JS (2007) Efficacy of multidetector row computed tomography of the spine in patients with multiple myeloma: comparison with magnetic resonance imaging and fluorodeoxyglucose-positron emission tomography. J Comput Assist Tomogr 31:342-347 (Pubitemid 46849898)
18. International myeloma working group (2003) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 121(5):749-757
19. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, Melton LJ III (2002) A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 346:564-569 (Pubitemid 34438817)
20. Mahnken AH, Wildberger JE, Gehbauer G, Schmitz-Rode T, Blaum M, Fabry U, Gunther RW (2002) Multidetector CT of the spine in multiple myeloma: comparison with MR imaging and radiography. Am J Roentgenol 178:1429-1436 (Pubitemid 34547826)
21. Moulopoulos LA, Dimopoulos MA, Smith TL, Weber DM, Delasalle KB, Libshitz HI, Alexanian R (1995) Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol 13:251-256
22. Mulkern RV, Schwartz RB (2003) In re: characterization of benign and metastatic vertebral compression fractures with quantitative diffusion MR imaging. Am J Neuroradiol 24(7):1489-1490; author reply 1490-1491
23. Nosas-Garcia S (2004) Dynamic contrast-enhanced MRI for assessing the disease activity of multiple myeloma: comparison with histological and clinical markers. Diss Med Fak University, Heidelberg
24. Nosas-Garcia S, Moehler T, Wasser K, Kiessling F, Bartl R, Zuna I, Hillengass J, Goldschmidt H, Kauczor HU, Delorme S (2005) Dynamic contrast-enhanced MRI for assessing the disease activity of multiple myeloma: a comparative study with histology and biochemical markers. J Magn Reson Imaging 22:154-162 (Pubitemid 40885141)
25. Ooi GC, Chim JC, Au WY, Khong PL (2006) Radiologic manifestations of primary solitary extramedullary and multiple solitary plasmacytomas. Am J Roentgenol 186:821-827 (Pubitemid 46100270)
26. Raya JG, Dietrich O, Reiser MF, Baur-Melnyk A (2006) Methods and applications of diffusion imaging of vertebral bone marrow. J Magn Reson Imaging 24:1207-1220 (Pubitemid 44871863)
27. Vande Berg BC, Lecouvet FE, Michaux L, Labaisse M, Malghem J, Jamart J, Maldague BE, Ferrant A, Michaux JL (1996) Stage I multiple myeloma: value of MR imaging of the bone marrow in the determination of prognosis. Radiology 201:243-246
28. Walker R, Barlogie B, Haessler J, Tricot G, Anaissie E, Shaughnessy JD Jr, Epstein J, van Hemert R, Erdem E, Hoering A, Crowley J, Ferris E, Hollmig K, van Rhee F, Zangari M, Pineda-Roman M, Mohiuddin A, Yaccoby S, Sawyer J, Angtuaco EJ (2007) Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol 25:1121-1128 (Pubitemid 46596765)
29. Wasser K, Moehler T, Neben K, Nosas S, Heiss J, Goldschmidt H, Hillengass J, Düber C, Kauczor HU, Delorme S (2004) Dynamische MRT des Knochenmarks zum Monitoring des Multiplen Myeloms unter Thalidomid-Monotherapie oder Kombination mit CED-Chemotherapie. Fortschr Röntgenstr 176:1285-1295 (Pubitemid 39237189)
30. Wasser K, Moehler T, Nosas-Garcia S, Rehm C, Bartl R, Goldschmidt H, Düber C, Kauczor HU, Delorme S (2005) Korrelation zwischen MRT und Histopathologie des Knochenmarks bei Patienten mit Multiplem Myelom. Fortschr Röntgenstr 177:1116-1122 (Pubitemid 41159025)
31. Zamagni E, Nanni C, Patriarca F, Englaro E, Castellucci P, Geatti O, Tosi P, Tacchetti P, Cangini D, Perrone G, Ceccolini M, Brioli A, Buttignol S, Fanin R, Salizzoni E, Baccarani M, Fanti S, Cavo M (2007) A prospective comparison of 18 F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica 92:50-55 (Pubitemid 46232657)
32. Zechmann C, Giesel FL, Hillengass J, Mehndiratta A, Delorme S, Moehler M (2007) Where is the primary tumor? Lancet 370:1800